# A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

> **NCT04538742** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 245 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Durvalumab
- **DRUG:** Paclitaxel
- **DRUG:** Pertuzumab
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT04538742
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-28
- **Primary completion:** 2025-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04538742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04538742, "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04538742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*